|
 |
| home > ebr > spring 2003 > variant creutzfeldt-jakob disease: safety of blood and plasma products |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
Transmissible spongiform encephalopathies (TSEs) are rare but invariably fatal neurodegenerative disorders affecting both animals and humans. The infectious agent is a modified form of a naturally occurring protein, composed largely of a self-replicating protein referred to as a prion.
In 1996 a new variant of Creutzfeldt-Jakob disease (vCJD) was described in Great Britain. Cases of vCJD are very rare and have occurred primarily in Great Britain. According to the British Department of Health, as of 6th January 2003 the number of probable or confirmed cases of vCJD in the UK had risen to 129. In addition, there have been six cases in France, one in the Republic of Ireland and one in Italy as well as one in the US. (This last case had been a resident in the UK but it is regarded as a US case. This is because cases are normally assigned to the country of residence at the time of onset of symptoms.)
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Sonja Lenz, Study Director, Klaus Kellings, Business Development Regional Manager, and Helga Siakkou, Quality Control Manager, at NewLab BioQuality AG
Sonja Lenz has been Study Director for prion studies at NewLab BioQuality AG since 2001. She studied Chemical Engineering at the Niederrhein University of Applied Sciences in Krefeld, and at NewLab she was responsible for establishing and validating the Western blots used in these studies.
Sonja has also performed several GLP-compliant studies whose results have been presented at various international meetings.
Dr Klaus Kellings works in the Business Development department at NewLab BioQuality AG. Prior to this position, he acted as Study Director for Virology at NewLab, responsible for viral and prion process validation studies. He gained experience in prion research during his studies in Biophysics at the University of Dьsseldorf and his post-doctoral research at the University of California in San Francisco. This experience has been invaluable in establishing the prion techniques used at NewLab.
Dr Helga Siakkou is currently Quality Control Manager at NewLab. She obtained her degree in Biochemistry at the State University of Kharkov, Ukraine, and a PhD in Molecular Biology and Virology from the Academy of Sciences in Berlin, Germany. Her research interests lie primarily in the area of retrovirus research. Helga has worked at NewLab BioQuality AG since 1994.
|
|
|
|
|
|
 |
Industry Events |
 |
ICSE South America
17-19 August 2010, Buenos Aires, Argentina
ICSE is the international stage for companies providing outsourcing services in clinical trials, contract research, custom manufacturing, biotechnology, IT, analytical services, packaging services and logistics. The first ICSE SA event was launched in 2008. For years ICSE has been connecting buyers and sellers in the market of (bio)pharmaceutical and pharma-related contract services. ICSE SA is a Pavilion within CPhI SA.
More info >> |
|
 |
News and Press Releases |
 |
PharmaBrand Summit 2010
Top pharmaceutical executives shared best practices at the PharmaBrand Summit
2010, which took place on the 21st to 23rd June 2010 in Monte-Carlo, Monaco
and was organised by Marcus Evans
More info >> |
|
  |
